Pre-clinical studies by Taylor et al.3 proposed that FLT3 inhibitor priming could induce leukemic progenitors into S-phase, thereby sensitising FLT3-ITD-mutant AML to subsequent chemotherapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.